Sona Nanotech Closes Over-Subscribed Private Placement Financing to Raise $2,527,012 in Gross Proceeds

Sona Nanotech Inc. (CSE: SONA,OTC:SNANF) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has closed its over-subscribed private placement that was announced on July 31, 2026 with the issuance of 8,423,372 common shares (each, a "Share") at $0.30 per share. (the "Financing").  All securities issued pursuant to the Financing will be subject to a hold period of four months and one day from the date of issuance.

As previously disclosed, Sona intends to use the net proceeds of the Financing for advancing studies to support the clinical advancement and continuing research and development work on its Targeted Hyperthermia Therapy^TM ("THT") oncology treatment, as well as for general working capital purposes. 

Directors of the Company subscribed for 300,000 shares. Such participation is considered to be "related party transactions" within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company relied on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the Offering as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61-101). 

About Sona Nanotech Inc.

Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, that uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion, an approach aligned with the melanoma research community's active focus on converting immunogenically 'cold' tumors, which resist immunotherapy, into 'hot' tumors that the immune system can recognize and attack, thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy; impact and effectiveness of Sona's THT cancer treatment; the timing and receipt of expected positive histological results supporting first-in-man treatment results obtained to date, including the anticipated design, conduct, and outcomes of the IGNITE-THT and PRIME-THT clinical studies; potential future applications of Sona's THT cancer treatment, including the estimated addressable patient population for early-stage melanoma; the timing and completion of Sona's proposed Canadian pilot study and Sona's preclinical and clinical study plans and the potential market impacts of such studies. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to secure the remaining required regulatory approvals for its clinical trials, including the ITA; enroll study participants in a timely manner, successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, the risk that THT may not prove to have the benefits currently reported and anticipated, and general economic, market, competitive and business conditions . There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE Sona Nanotech Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2026/10/c4483.html